A Study of JADE101 for IgA Nephropathy
This study is testing a drug called JADE101 in people with IgA nephropathy (a kidney disease). JADE101 is given as a shot under the skin. The main goal is to see how safe JADE101 is and if people can tolerate it, by tracking any side effects for about 100 weeks. You might be able to join if you are between 18 and 60 years old, have biopsy-confirmed IgA nephropathy, and your eGFR (a measure of kidney function) is 30 mL/min/1.73 m2 or higher. You also need to be on stable doses of certain blood pressure medications (ACEi or ARB) for at least 12 weeks. The study is currently unclear about its recruitment status.
- Study design
- This is an open-label Phase 2 study, meaning both you and the study team will know you are receiving JADE101. It plans to include about 30 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your safety will be monitored from the first day of treatment through 100 weeks.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Study of JADE101 in Participants With Immunoglobulin A Nephropathy
At a glance
Conditions
Where it's being run
15 sites across 8 statesStudy leadership
- Li Li, MD · STUDY_DIRECTOR · Jade BioSciences
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Incidence of treatment-emergent adverse events (safety and tolerability)Day 1 through 100 weeks
The proportion of participants who experience one or more adverse events that begin or worsen after the first dose of study drug